Cargando…
Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulos...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848631/ https://www.ncbi.nlm.nih.gov/pubmed/35170870 http://dx.doi.org/10.1002/prp2.934 |
_version_ | 1784652293582356480 |
---|---|
author | Russom, Mulugeta Fitsum, Yodit Debesai, Merhawi Russom, Natnael Bahta, Merhawi |
author_facet | Russom, Mulugeta Fitsum, Yodit Debesai, Merhawi Russom, Natnael Bahta, Merhawi |
author_sort | Russom, Mulugeta |
collection | PubMed |
description | Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulosin and priapism is causal. All currently available evidence such as experimental, biological, toxicological, published studies, and safety data mined from the WHO global pharmacovigilance database was systematically organized into the Austin Bradford Hill causality assessment framework. In the international pharmacovigilance database, a strong association between tamsulosin and priapism (IC(025) = 4.1; PRR(025) = 19.9; ROR(025) = 20) was observed. There were 122 cases of priapism associated with tamsulosin submitted to the database from 23 countries. In 87.7% of the cases, tamsulosin was reported as a ‘sole suspect,’ and in 50.8%, it was the only drug administered. In several patients, priapism resolved following discontinuation of tamsulosin and recurred after its reintroduction. Both in the published and unpublished data, for majority of the cases, the time to onset of priapism was within few days following the first intake of tamsulosin. Cases of priapism, particularly those published, were consistent in their clinical features with patients experiencing prolonged painful erection that required aspiration of cavernosal blood, irrigation of the corpora cavernosa, and treatment with vasopressors. Other alpha‐adrenergic blocking agents that are structurally analogous with tamsulosin have also been associated with priapism. In several cases, tamsulosin was used off‐label, for the treatment of ureteral calculi expulsion. Eight patients experienced priapism that ended up with serious complications such as ejaculation disorders and erectile dysfunction. The currently available totality of evidence suggests that the association of tamsulosin and priapism is causal. Healthcare professionals are therefore recommended to cautiously prescribe tamsulosin and ensure that consumers are aware of the potential risk of priapism. |
format | Online Article Text |
id | pubmed-8848631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88486312022-02-25 Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria Russom, Mulugeta Fitsum, Yodit Debesai, Merhawi Russom, Natnael Bahta, Merhawi Pharmacol Res Perspect Original Articles Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulosin and priapism is causal. All currently available evidence such as experimental, biological, toxicological, published studies, and safety data mined from the WHO global pharmacovigilance database was systematically organized into the Austin Bradford Hill causality assessment framework. In the international pharmacovigilance database, a strong association between tamsulosin and priapism (IC(025) = 4.1; PRR(025) = 19.9; ROR(025) = 20) was observed. There were 122 cases of priapism associated with tamsulosin submitted to the database from 23 countries. In 87.7% of the cases, tamsulosin was reported as a ‘sole suspect,’ and in 50.8%, it was the only drug administered. In several patients, priapism resolved following discontinuation of tamsulosin and recurred after its reintroduction. Both in the published and unpublished data, for majority of the cases, the time to onset of priapism was within few days following the first intake of tamsulosin. Cases of priapism, particularly those published, were consistent in their clinical features with patients experiencing prolonged painful erection that required aspiration of cavernosal blood, irrigation of the corpora cavernosa, and treatment with vasopressors. Other alpha‐adrenergic blocking agents that are structurally analogous with tamsulosin have also been associated with priapism. In several cases, tamsulosin was used off‐label, for the treatment of ureteral calculi expulsion. Eight patients experienced priapism that ended up with serious complications such as ejaculation disorders and erectile dysfunction. The currently available totality of evidence suggests that the association of tamsulosin and priapism is causal. Healthcare professionals are therefore recommended to cautiously prescribe tamsulosin and ensure that consumers are aware of the potential risk of priapism. John Wiley and Sons Inc. 2022-02-16 /pmc/articles/PMC8848631/ /pubmed/35170870 http://dx.doi.org/10.1002/prp2.934 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Russom, Mulugeta Fitsum, Yodit Debesai, Merhawi Russom, Natnael Bahta, Merhawi Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title | Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title_full | Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title_fullStr | Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title_full_unstemmed | Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title_short | Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria |
title_sort | tamsulosin and risk of priapism: a causality assessment using austin bradford hill criteria |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848631/ https://www.ncbi.nlm.nih.gov/pubmed/35170870 http://dx.doi.org/10.1002/prp2.934 |
work_keys_str_mv | AT russommulugeta tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria AT fitsumyodit tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria AT debesaimerhawi tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria AT russomnatnael tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria AT bahtamerhawi tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria |